Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Ready to sweat, detox, and glow
However, the exogenous administration of GLP-1RAs can mitigate sympathetic excitability by suppressing the peripheral chemoreflex originating from the carotid body.467 Under hyperglycemic conditions, GLP-1RAs regulate hypertension by inhibiting carotid body function.468 Specifically, these agents can attenuate the excitability of carotid body cells and diminish sympathetic activation, ultimately leading to a reduction in sympathetic responses.465 This modulatory effect holds promise for ameliorating sympathetic activity in individuals with hypertension, as these agents lower blood pressure levels.469 Importantly, the GLP-1-carotid body pathway may represent a novel therapeutic target for managing cardiovascular metabolism and treating patients with diabetes and hypertension who exhibit heightened sympathetic activity.465 (Fig
doi:10.1038/s41598-018-22081-7 (PMID 29483571) Ruf S, Rajagopal S, Kadnur SV, et al
Novo Nordisk earned approval for a daily oral version of semaglutide (Rybelsus) in T2D (NCT02906930)
